Author | Saroj Vadhan-raj, MD


Every-2-Week Darbepoetin Alfa Is Comparable to rHuEPO in Treating Chemotherapy-Induced Anemia

October 01, 2002

ByBarry Mirtsching, MD|Veena Charu, MD|Saroj Vadhan-raj, MD|Alan B. Colowick, MD, MPH|Gregory Rossi, PhD|Dianne Tomita, MPH|William P. Mcguire Iii, MD

The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 µg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by

Recombinant Human Thrombopoietin in Myelosuppressive Chemotherapy

July 01, 2001

BySaroj Vadhan-raj, MD

Recombinant human thrombopoietin (rhTPO) is a full-lengthglycosylated molecule that has been under evaluation in the setting of

Thrombopoietin: Biology and Potential Clinical Applications

November 01, 1998

ByDebra Prow, MD|Saroj Vadhan-raj, MD

After an almost 40-year search for a primary regulatory of platelet production, thrombopoietin has recently been purified and cloned. Thrombopoietin regulates all stages in the production of platelets by promoting both the